296 related articles for article (PubMed ID: 12709680)
1. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
Righetti M; Ferrario GM; Milani S; Serbelloni P; La Rosa L; Uccellini M; Sessa A
Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680
[TBL] [Abstract][Full Text] [Related]
2. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
Righetti M; Serbelloni P; Milani S; Ferrario G
Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
[TBL] [Abstract][Full Text] [Related]
4. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
[TBL] [Abstract][Full Text] [Related]
5. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
6. Different doses of oral folic acid for homocysteine-lowering therapy in patients on hemodialysis: a randomized controlled trial.
Ossareh S; Shayan-Moghaddam H; Salimi A; Asgari M; Farrokhi F
Iran J Kidney Dis; 2009 Oct; 3(4):227-33. PubMed ID: 19841527
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.
Nakhoul F; Abassi Z; Plawner M; Khankin E; Ramadan R; Lanir N; Brenner B; Green J
Isr Med Assoc J; 2004 Apr; 6(4):213-7. PubMed ID: 15115259
[TBL] [Abstract][Full Text] [Related]
8. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.
Dierkes J; Domröse U; Ambrosch A; Bosselmann HP; Neumann KH; Luley C
Clin Nephrol; 1999 Feb; 51(2):108-15. PubMed ID: 10069646
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients.
Azadibakhsh N; Hosseini RS; Atabak S; Nateghiyan N; Golestan B; Rad AH
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):779-88. PubMed ID: 19736473
[TBL] [Abstract][Full Text] [Related]
10. [Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation].
Kárpáti I; Balla J; Szóke G; Bereczky Z; Páll D; Ben T; Toma K; Katona E; Mohácsi A; Paragh G; Varga Z; Kakuk G; Muszbek L
Orv Hetil; 2002 Jul; 143(27):1635-40. PubMed ID: 12180000
[TBL] [Abstract][Full Text] [Related]
11. Elevated homocysteine levels in patients with end-stage renal disease.
Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
[TBL] [Abstract][Full Text] [Related]
12. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
[TBL] [Abstract][Full Text] [Related]
13. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine and renal disease.
van Guldener C; Robinson K
Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
[TBL] [Abstract][Full Text] [Related]
15. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients.
Alvares Delfino VD; de Andrade Vianna AC; Mocelin AJ; Barbosa DS; Mise RA; Matsuo T
Nutrition; 2007 Mar; 23(3):242-7. PubMed ID: 17321110
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
17. [Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis].
Sydor A; Drozdz M; Kraśniak A; Miłkowski A; Chmiel G; Małczak J; Zabawa-Hołyś S; Moskal K; Podwysocki A; Szmigielski M; Czarnecka D; Gozdecka H; Kowalczyk-Michałek M; Szczeklik A; Wiecek A; Sułowicz W
Przegl Lek; 2002; 59(12):962-7. PubMed ID: 12731367
[TBL] [Abstract][Full Text] [Related]
18. Observational study on markers of cardiovascular risk in renal patient: conventional hemodialysis vs. haemofiltration online.
Melero-Rubio E; Párraga-Díaz M; Gómez-Sánchez MP; Pellicer-Villaescusa S; Merchán-Mayado E
J Ren Care; 2009 Dec; 35(4):201-4. PubMed ID: 19909413
[TBL] [Abstract][Full Text] [Related]
19. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
[TBL] [Abstract][Full Text] [Related]
20. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.
Heinz J; Kropf S; Domröse U; Westphal S; Borucki K; Luley C; Neumann KH; Dierkes J
Circulation; 2010 Mar; 121(12):1432-8. PubMed ID: 20231532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
